A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336 · Not yet recruiting

Last updated 2026-07-12

This study is testing the safety and effects of the medication orforglipron compared to dulaglutide in children and adolescents with type 2 diabetes.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 170 people Planned (estimated).

Who can join Ages 10–17 · all sexes

Timeline Started 2026-09 · est. completion 2030-03

Where 71 sites · Belgium, Brazil, India, Italy, Japan, Mexico, South Korea, Spain, Taiwan, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT07668336 ↗

Description as written by the study sponsor.

This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Dulaglutide also known as LY2189265 Drug

Administered SC

Main thing measured	Change from Baseline in Hemoglobin A1c (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	dulaglutide, orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07668336 ↗